PHARMACY

FlavorX Flavoring System helps the medicine go down

BY Alaric DeArment

BOSTON Mary Poppins may have observed a spoonful of sugar’s ability to help wash medicine down, but a mouthful of bitter syrup continues to be an unpleasant experience for any child.

FlavorX, a company based in the Baltimore and Washington area, has designed an automation dispensing aid designed to improve the palatability of medicines for children.

The FlavorX Flavoring System uses a bitterness suppressor and sweetness enhancer to allow pharmacists to mask the taste of many prescription and OTC medications in a wide variety of flavors, speeding up the flavoring process while giving the pharmacist complete control of the process.

According to some research, 86% of parents found that flavoring by the pharmacist influenced children’s success in taking the asthma drug prednisone, while 40% of children completed their therapies without flavoring.

“These figures clearly illustrate that flavoring medications promotes better patient compliance and increases positive clinical outcomes,” FlavorX president and CEO Stuart Amos said in a statement. “We wanted to help pharmacists fill a flavored prescription faster and meet the increasing demand as well as help patients get well.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Caraco settles patent suit over cancer generic

BY Alaric DeArment

DETROIT A generic drug maker announced Monday that it had settled patent litigation over a generic version of a cancer drug.

Caraco Pharmaceutical Labs said it reached a settlement with MedImmune over a generic version of the drug Ethyol (amifostine). MedImmune had filed the suit in the U.S. District Court for the District of Maryland.

Under the settlement, MedImmune granted Caraco a license to certain patents that permit Caraco to continue marketing its generic version of Ethyol in the United States.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Biosimilars bill passed by House committee draws response from GPhA

BY Alaric DeArment

NEW YORK A House committee vote has brought a pathway for biosimilars one step closer to reality, but not in a way that pleases everyone.

The House Energy and Commerce Committee voted 47-11 Friday to pass an amendment to the healthcare reform bill that would give biotech drugs 12 years of market exclusivity before they face competition from biosimilars.

“We are sincerely disappointed that some members of the House Energy and Commerce Committee have decided to put brand pharmaceutical profits before patient needs,” Generic Pharmaceutical Association president and CEO Kathleen Jaeger said in a statement. “The amendment passed tosses patient needs out the window.”

In March, Reps. Henry Waxman and Anna Eshoo, both California Democrats, sponsored competing bills in Congress to allow a regulatory pathway for biosimilars. Waxman’s bill would give biotech drugs five years’ market exclusivity before facing biosimilar competition, like the Hatch-Waxman Act of 1984, which created a pathway for generic pharmaceutical drugs. Eshoo’s bill would grant 12 to 14 years of exclusivity. The short-exclusivity plan has the support of the generic drug industry, patient advocates, pharmacy trade groups and The Washington Post editorial page, though legislation to allow longer exclusivity periods has advanced further in the House and Senate.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?